1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>United States

Alios Purchase Boosts J&J Anti-Infectives Game, Especially Hep C

A pair of promising preclinical nucleoside polymerase inhibitors for hepatitis C might be the driving force behind J&J’s $1.75 billion buyout of Alios, even though the privately held biotech’s most advanced candidate, ALS-8176, in Phase II for respiratory syncytial virus, also is a fit for J&J’s anti-infective strategy.

Johnson & Johnson sees Alios BioPharma Inc. as a perfect fit for advancing its anti-infective drug-development strategy, with a Phase II candidate for respiratory syncytial virus and a pair of preclinical hepatitis C compounds that bolster the commercial viability of the pharma’s hepatitis C blockbuster Olysio (simeprevir).

The twin primary areas of focus for Janssen Pharmaceutical Cos

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America